Press releases
- Launch of Phase 3 clinical trial with Nefecon in Japan
- Calliditas provides setanaxib patent update
- Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
- Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
- Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
- Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
- Calliditas Q1 report, January - March 2024
- In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
- Invitation to the presentation of Calliditas´s interim report January - March 2024
- Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
More ▼
Key statistics
On Thursday, Calliditas Therapeutics AB (LC8:DUS) closed at 17.50, -4.53% below its 52-week high of 18.33, set on Jun 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.29 |
---|---|
High | 17.50 |
Low | 17.29 |
Bid | 17.44 |
Offer | 17.72 |
Previous close | 17.53 |
Average volume | 0.00 |
---|---|
Shares outstanding | 59.94m |
Free float | 47.59m |
P/E (TTM) | -- |
Market cap | 12.36bn SEK |
EPS (TTM) | -9.78 SEK |
Data delayed at least 15 minutes, as of Jul 25 2024 18:31 BST.
More ▼